Haemolytic uremic syndrome and gemcitabine: Jaundice is not always progression in cholangiocarcinoma
- 22 February 2012
- journal article
- letter
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 51 (5) , 687-688
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract CancerNew England Journal of Medicine, 2010
- Hypersensitivity reaction and acute immune-mediated thrombocytopenia from oxaliplatin: two case reports and a review of the literatureJournal of Hematology & Oncology, 2010
- Is therapeutic plasma exchange indicated for patients with gemcitabine‐induced hemolytic uremic syndrome?Journal of Clinical Apheresis, 2009
- Autoantibodies in haemolytic uraemic syndrome (HUS)Thrombosis and Haemostasis, 2009
- Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II studyBritish Journal of Cancer, 2008
- Hemolytic uremic syndrome following the infusion of oxaliplatin: case reportBMC Clinical Pharmacology, 2006
- Chemotherapy of advanced NSCLC in special patient populationAnnals of Oncology, 2006
- Haemolytic uraemic syndrome: An overview (Review Article)Nephrology, 2006
- Gemcitabine‐associated thrombotic microangiopathyCancer, 2004
- Supraadditive effect of 2 ′ ,2 ′ -difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell linesCancer Chemotherapy and Pharmacology, 1999